高级检索
当前位置: 首页 > 详情页

Effect of shikonin on multidrug resistance in HepG2: The role of SIRT1

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China [2]Department of Clinical Medicine, Medical College, Wuhan University of Science and Technology, Wuhan, China
出处:
ISSN:

关键词: Apoptosis caspase-3 hepatocellular cancer HepG2 multidrug resistance 1/P-gp NAD(+)-dependent deacetylase paclitaxel rhodamin-123 sirtuin 1

摘要:
Context: Overexpression of SIRT1 is considered to enhance the resistance of HepG2 cells to irradiation. Shikonin, a naturally occurring naphthoquinone compound, displays anticancer effects and circumvents cancer drug resistance. Objectives: This study investigated the MDR reversal effect of shikonin induced by the overexpression of SIRT1. Materials and methods: The overexpression of SIRT1 in HepG2 cells was established by lentivirus infection. Five days after transduction, real-time quantitative polymerase chain reaction and western blotting were used to detect the expression of SIRT1 and MDR1/P-gp. Drug resistance was also evaluated by flow cytometry after rhodamine-123 staining. On day 5, the multidrug resistance cells were treated by shikonin (10(-7), 10(-6), and 10(-5) mmol/L) one time. The cell viability was detected by the MTT assay, and apoptosis was evaluated by Hoechst 33342 staining and caspase-3 activity 24 h after shikonin treatment. Results: Overexpression of SIRT1 decreased rhodamine-123 staining and successfully produced the R-HepG2 cell line. Compared with HepG2, the expression of MDR1/P-gp mRNA (3.45 +/- 0.35) and protein (1.40 +/- 0.05) were both upregulated in R-HepG2. Shikonin inhibited cell viability (from 93.9 +/- 2.1 to 66.7 +/- 1.5%), induced apoptosis of R-HepG2 (apoptotic ratio from 3.5 +/- 0.8 to 47.5 +/- 2.7%, caspase-3 activity from 103.5 +/- 1.9 to 329.2 +/- 14.9%, respectively), downregulated the mRNA and protein expression of SIRT1 and MDR1/P-gp, and decreased rhodamin 123 efflux. Discussion and conclusion: In the present study, we demonstrated that shikonin is able to overcome drug resistance in hepatocellular carcinoma cells, and the mechanism is related to the SIRT1-MDR1/P-gp signaling pathway.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 医学实验技术 4 区 药学 4 区 植物科学
最新[2023]版:
大类 | 3 区 医学
小类 | 2 区 医学实验技术 2 区 药学 2 区 植物科学
JCR分区:
出版当年[2015]版:
Q2 PLANT SCIENCES Q3 PHARMACOLOGY & PHARMACY Q3 MEDICAL LABORATORY TECHNOLOGY
最新[2023]版:
Q1 MEDICAL LABORATORY TECHNOLOGY Q1 PHARMACOLOGY & PHARMACY Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China
通讯作者:
通讯机构: [1]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China [*1]Department of Medical Oncology, Sichuan Cancer Hospital, forth of south Renmin Road 55#, Chengdu 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43373 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号